Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.

Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer. - Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012018

Enrollment

Registered

2013-10-10

Start date

2013-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Eribulin, Trastuzumab and Pertuzumab

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Patients with pathologically confirmed metastatic/reccurent breast cancer. 2) HER2 positive. 3) Age >=20 and 80=< 4) Performance status (PS, ECOG scale): 0-2. 5) History of one or more cytotoxic agent and anti-HER2 therapy. 6) Adequate organ functions, measured as follows: Neutrophils: >= 1,500/mm3 Platelet: >= 100,000/mm3 Total birilbin: <= 1.5 x ULN AST (GOT): <= 3.0 x ULN ALT (GPT): <= 3.0 x ULN Serum creatinine: <= 1.5 x ULN 7) LVEF: >= 50% 8) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Past history of severe hypersensitivity. 2) History of eribulin use during 6 months prior to consent. 3) Active multiple primary malignancy. 4) Patients with uncontrolled infection. 5) Patient with disease requiring emergent intervention. 6) Patients with progressive brain metastasis requiring treatment during 6 months prior to consent. 7) Patients with severe complications. 8) Pregnant or breastfeeding. 9) Patients who deny contraception during this study. 10) Any other cases that the attending doctor judges not appropriate to enroll to this study.

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactMikiya Ishihara

Mie University Hospital Dep. of Hematology and Oncology

mishihara@clin.medic.mie-u.ac.jp059-232-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026